SpectraCure AB Quarterly report (1 April to 30 June) 2019

Second quarter (1 April – 30 June 2019)

  •  Net sales for the quarter amounted to TSEK 0 (0).
  •  Other income amounted to TSEK 663 (406).
  •  Profit after tax amounted to TSEK -4 149 (-4 028).
  •  Corresponding to SEK -0,05 (-0,07) per share.
  •  Operating cash flow was TSEK -3 547 (-2 977).
  •  Cash as of 30 June amounted to TSEK 32 619 (7 025).
  •  Equity ratio 79 (83)%.

Half-year (1 January – 30 June 2019) 

  •  Net sales for the quarter amounted to TSEK 0 (0).
  •  Other income amounted to TSEK 1 313 (687).
  •  Profit after tax amounted to TSEK -6 925 (-6 650).
  •  Corresponding to SEK -0,08 (-0,11) per share.
  •  Operating cash flow was TSEK -3 576 (-4 364).

For further information, please contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46 (0) 70 815 21 90

Certified Adviser is G&W Fondkommission, e-mail: ca@gwkapital.se, phone: +46(0) 8 503 000 50 

This information is information that SpectraCure AB is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on August 21st, 2019 14.00.

Half-year report 2019 Q2
SpectraCure logo

SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects. 

Facebook Linkedin Envelope